[go: up one dir, main page]

PE20080432A1 - CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS - Google Patents

CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Info

Publication number
PE20080432A1
PE20080432A1 PE2007000999A PE2007000999A PE20080432A1 PE 20080432 A1 PE20080432 A1 PE 20080432A1 PE 2007000999 A PE2007000999 A PE 2007000999A PE 2007000999 A PE2007000999 A PE 2007000999A PE 20080432 A1 PE20080432 A1 PE 20080432A1
Authority
PE
Peru
Prior art keywords
pyridyl
amino
substituted
phenyl
compositions
Prior art date
Application number
PE2007000999A
Other languages
Spanish (es)
Inventor
Xiangping Qian
Jeffrey T Finer
Pu-Ping Lu
Chihyan Grace Chuang
Bradley P Morgan
Morgans
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Publication of PE20080432A1 publication Critical patent/PE20080432A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA X, DONDE W1 ES N, CR6; W2 ES N, CR4, SIEMPRE QUE AMBOS W1 Y W2 NO SON N; R1 Y R4 SON CADA UNO H, CIANO, HALO, HIDROXI, AZIDO, ENTRE OTROS; Z1 ES H, ARILO SUSTITUIDO O NO, HETEROARILO, ENTRE OTROS; Z2 ES H, CARBOXILO, AMIDINO SUSTITUIDO O NO, ACILO, ENTRE OTROS; Z3 ES H, HALOGENO, ALQUILO SUSTITUIDO O NO; R3 ES H, ALQUILO SUSTITUIDO O NO; R6 ES H, ACILO, CIANO, HALO, AZIDO, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: N-METIL-{6-FENIL-2-[(2-FENILETIL)AMINO]-(3-PIRIDIL)}CARBOXAMIDA; {2-[(3-METILBUTIL)AMINO]-6-FENIL-(3-PIRIDIL)}-N-(3-PIRIDILMETIL)CARBOXAMIDA; 2-{[(METILSULFONIL)AMINO]METIL}PIPERIDIL-6-FENIL-2-[(2-(2-PIRIDIL)ETIL)AMINO](3-PIRIDIL)CETONA; ENTRE OTROS. REFERIDA TAMBIEN A UN PROCEDIMIENTO DE PREPARACION Y UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN MIOSINA DEL MUSCULO LISO Y/O MIOSINA NO MUSCULAR UTILES EN EL TRATAMIENTO DE HIPERTENSION, ASMA, GLAUCOMA, DERRAME CEREBRAL, ENTRE OTROSREFERS TO A COMPOUND OF FORMULA X, WHERE W1 IS N, CR6; W2 IS N, CR4, PROVIDED THAT BOTH W1 AND W2 ARE NOT N; R1 AND R4 ARE EACH H, CYANE, HALO, HYDROXY, AZIDO, AMONG OTHERS; Z1 IS H, ARYL, SUBSTITUTED OR NOT, HETEROARYL, AMONG OTHERS; Z2 IS H, CARBOXYL, AMIDINE SUBSTITUTED OR NOT, ACIL, AMONG OTHERS; Z3 IS H, HALOGEN, ALKYL SUBSTITUTED OR NOT; R3 IS H, RENTAL SUBSTITUTED OR NOT; R6 IS H, ACILO, CYANE, HALO, AZIDO, AMONG OTHERS. PREFERRED COMPOUNDS ARE: N-METHYL- {6-PHENYL-2 - [(2-PHENYLETHYL) AMINO] - (3-PYRIDYL)} CARBOXAMIDE; {2 - [(3-METHYLBUTYL) AMINO] -6-PHENYL- (3-PYRIDYL)} - N- (3-PYRIDYLMETHYL) CARBOXAMIDE; 2 - {[(METHYLSULFONYL) AMINO] METHYL} PIPERIDYL-6-PHENYL-2 - [(2- (2-PYRIDYL) ETHYL) AMINO] (3-PYRIDYL) KETONE; AMONG OTHERS. ALSO REFERRED TO A PREPARATION PROCEDURE AND A PHARMACEUTICAL COMPOSITION. SUCH COMPOUNDS MODULATE SMOOTH MUSCLE MYOSIN AND / OR NON-MUSCULAR MYOSIN USEFUL IN THE TREATMENT OF HYPERTENSION, ASTHMA, GLAUCOMA, BRAIN SPILL, AMONG OTHERS

PE2007000999A 2006-08-01 2007-08-01 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS PE20080432A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83501006P 2006-08-01 2006-08-01
US83490306P 2006-08-01 2006-08-01
US83518306P 2006-08-01 2006-08-01
US83490106P 2006-08-01 2006-08-01
US83490406P 2006-08-01 2006-08-01
US83523606P 2006-08-02 2006-08-02

Publications (1)

Publication Number Publication Date
PE20080432A1 true PE20080432A1 (en) 2008-05-29

Family

ID=38997696

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000999A PE20080432A1 (en) 2006-08-01 2007-08-01 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS

Country Status (4)

Country Link
AR (1) AR062176A1 (en)
PE (1) PE20080432A1 (en)
TW (1) TW200823188A (en)
WO (1) WO2008016643A2 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7919511B2 (en) 2006-08-01 2011-04-05 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939534B2 (en) 2006-08-01 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7932270B2 (en) 2006-08-01 2011-04-26 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
US7939548B2 (en) 2006-08-02 2011-05-10 Cytokinetics, Inc. Certain chemical entities, compositions, and methods
EP2202228B1 (en) 2007-10-15 2014-12-10 Takeda Pharmaceutical Company Limited Amide compounds and use of the same
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
HRP20160967T1 (en) 2009-10-06 2016-10-07 Millennium Pharmaceuticals, Inc. Heterocyclic compounds useful as pdk1 inhibitors
US8377970B2 (en) 2009-10-08 2013-02-19 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel
US8993612B2 (en) 2009-10-08 2015-03-31 Rhizen Pharmaceuticals Sa Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
WO2014134391A1 (en) 2013-02-28 2014-09-04 Bristol-Myers Squibb Company Phenylpyrazole derivatives as potent rock1 and rock2 inhibitors
TW201444798A (en) 2013-02-28 2014-12-01 必治妥美雅史谷比公司 Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors
WO2015010832A1 (en) * 2013-07-22 2015-01-29 Syngenta Participations Ag Microbiocidal heterocyclic derivatives
JP2017214290A (en) * 2014-09-12 2017-12-07 田辺三菱製薬株式会社 Aromatic carboxylic acid amide compound
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
RS62639B1 (en) 2015-07-06 2021-12-31 Alkermes Inc Hetero-halo inhibitors of histone deacetylase
GB201604970D0 (en) 2016-03-23 2016-05-04 Syngenta Participations Ag Improvements in or relating to organic compounds
TWI770104B (en) 2017-01-11 2022-07-11 美商羅登醫療公司 Bicyclic inhibitors of histone deacetylase
JOP20180011A1 (en) 2017-02-16 2019-01-30 Gilead Sciences Inc Perulo derivatives [1, 2-b] pyridazine
PL3664802T3 (en) 2017-08-07 2022-07-11 Alkermes, Inc. Bicyclic inhibitors of histone deacetylase
TWI721483B (en) 2018-07-13 2021-03-11 美商基利科學股份有限公司 Pyrrolo[1,2-b]pyridazine derivatives
BR112022008753A2 (en) * 2019-11-06 2022-07-19 Remedy Plan Inc CANCER TREATMENTS TARGETED TO CANCER STEM CELLS
CN111393376B (en) * 2020-05-11 2022-05-13 安徽赛迪生物科技有限公司 Synthetic method of 2-chloropyrimidine-4-formic acid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4140853A (en) * 1975-04-18 1979-02-20 Schering Aktiengesellschaft Process for the preparation of aminopyridines
EP1740573A1 (en) * 2004-04-22 2007-01-10 Eli Lilly And Company Amides as bace inhibitors

Also Published As

Publication number Publication date
WO2008016643A2 (en) 2008-02-07
AR062176A1 (en) 2008-10-22
WO2008016643A3 (en) 2008-06-19
TW200823188A (en) 2008-06-01

Similar Documents

Publication Publication Date Title
PE20080432A1 (en) CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
JP4663984B2 (en) Thiadiazolyl piperazine derivatives useful for the treatment or prevention of pain
JP5956999B2 (en) Heteroaryl compounds and uses thereof
WO2008002596A3 (en) Adenosine a2a receptor antagonists
TW200800899A (en) Novel compounds
MX2009004900A (en) Thiazole and oxazole-substituted arylamides.
EA200802007A1 (en) COMPOUNDS POTENTIATING AMPA RECEPTOR AND APPLICATION OF THE SPECIFIED COMPOUNDS IN MEDICINE
JP2011527334A5 (en)
NO20076450L (en) Heterocyclic compounds as nicotinic acid receptor agonists for the treatment of dyslipidemia
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
DK1716152T3 (en) Condensed heterocyclic compounds and their use as metabotropic receptor antagonists in the treatment of gastrointestinal disorders
BR0207526A (en) Compound, pharmaceutical composition, and methods for treating pain, migraine, depression, anxiety, schizophrenia, parkinson's disease, or stroke
NZ547615A (en) Quinoline derivatives and use thereof as mycobacterial inhibitors
MX2012004848A (en) Tricyclic heterocyclic compounds.
NO20091596L (en) Benzoylamino Heterocyclic Compounds as Glucokinase (GLK) Activators
PL1735278T3 (en) Histamine h3 receptor agents, preparation and therapeutic uses
KR20120123691A (en) Pharmaceutical compositions for the treatment of pain and other indicatons
WO2008056259A3 (en) Oxazole derivatives as positive allosteric modulators of metabotropic glutamate receptors
MY148375A (en) Delta and epsilon crystal forms of imatinib mesylate
NO20092464L (en) Solid forms of racemic ilaprazole
EA200501595A1 (en) AZABICYCLIC DERIVATIVES AS ANTAGONISTS OF MUSCARINE RECEPTOR
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
RU2450010C2 (en) SUBSTITUTED IMIDAZO{2,1-b}THIAZOLES AND APPLICATION THEREOF FOR MAKING DRUG PREPARATIONS
EA200900245A1 (en) HEMOKIN RECEPTOR ACTIVITY MODULATORS, CRYSTAL FORMS AND METHOD FOR THEIR RECEPTION
DK1750703T3 (en) Method of reducing gastrointestinal toxicity caused by the administration of tegafur

Legal Events

Date Code Title Description
FC Refusal